RGC trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes RGC achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Regencell Bioscience Holdings Limited (RGC) has a Wall Street consensus price target of N/A, based on estimates from 4 covering analysts. The company has a market capitalization of $2.61B.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Hold, with 0 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, RGC trades at a trailing P/E of -222.4x.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NUVBNuvation Bio Inc. | $1.4B | $4.16 | $20.50 | +392.8% | Buy | — | 10 |
 AEYEAudioEye, Inc. | $155M | $12.37 | $21.00 | +69.8% | Buy | 11.9x | 7 |
 SIGASIGA Technologies, Inc. | $222M | $3.10 | — | — | Buy | 1.8x | 1 |
 LONALeonaBio, Inc. | $17M | $4.42 | — | — | — | — | — |
 PRAXPraxis Precision Medicines, Inc. | $7.7B | $277.62 | $611.69 | +120.3% | Buy | — | 18 |
 ACMRACM Research, Inc. | $2.9B | $44.61 | $122.75 | +175.2% | Buy | 20.1x | 10 |
 DFTXDefinium Therapeutics, Inc. | $4.5B | $33.27 | $20.00 | -53.3% | Buy | — | 1 |
 HALOHalozyme Therapeutics, Inc. | $12.3B | $103.63 | $110.00 | +6.1% | Buy | 12.0x | 27 |
 SYRSSyros Pharmaceuticals, Inc. | $10733 | $0.00 | — | — | — | — | — |
 CRVSCorvus Pharmaceuticals, Inc. | $886M | $10.54 | $27.00 | +156.2% | Buy | — | 13 |
Quick answers to the most common questions about buying RGC stock.
The consensus price target for RGC is $N/A, close to the current price of $5.27 (N/A% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
RGC has a consensus rating of "Hold" based on 4 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
RGC's current price is $5.27 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for RGC, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
RGC is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RGC stock forecast based on 4 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Hold".
RGC appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RGC analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.